Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

M (Brian) Fennerty, J. F. Johanson, C. Hwang, M. Sostek

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim: To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods: In this multicentre, randomized, double-blind, parallel-group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg (n = 498) or lansoprazole 30 mg (n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator-assessed resolution of symptoms and safety and tolerability. Results: Time to healing was significantly different (P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4% with esomeprazole 40 mg and 77.5% with lansoprazole 30 mg. Heartburn resolved at week 4 in 72% and 64% of patients who received esomeprazole and lansoprazole, respectively (P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions: With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume21
Issue number4
DOIs
StatePublished - Feb 15 2005

Fingerprint

Esomeprazole
Lansoprazole
Esophagitis
Heartburn
Omeprazole
Los Angeles
Therapeutics
Gastroesophageal Reflux
Research Personnel
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. / Fennerty, M (Brian); Johanson, J. F.; Hwang, C.; Sostek, M.

In: Alimentary Pharmacology and Therapeutics, Vol. 21, No. 4, 15.02.2005, p. 455-463.

Research output: Contribution to journalArticle

@article{f05d035c408248ca88a426387f81e859,
title = "Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis",
abstract = "Background: Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim: To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods: In this multicentre, randomized, double-blind, parallel-group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg (n = 498) or lansoprazole 30 mg (n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator-assessed resolution of symptoms and safety and tolerability. Results: Time to healing was significantly different (P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4{\%} with esomeprazole 40 mg and 77.5{\%} with lansoprazole 30 mg. Heartburn resolved at week 4 in 72{\%} and 64{\%} of patients who received esomeprazole and lansoprazole, respectively (P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions: With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.",
author = "Fennerty, {M (Brian)} and Johanson, {J. F.} and C. Hwang and M. Sostek",
year = "2005",
month = "2",
day = "15",
doi = "10.1111/j.1365-2036.2005.02339.x",
language = "English (US)",
volume = "21",
pages = "455--463",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

AU - Fennerty, M (Brian)

AU - Johanson, J. F.

AU - Hwang, C.

AU - Sostek, M.

PY - 2005/2/15

Y1 - 2005/2/15

N2 - Background: Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim: To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods: In this multicentre, randomized, double-blind, parallel-group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg (n = 498) or lansoprazole 30 mg (n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator-assessed resolution of symptoms and safety and tolerability. Results: Time to healing was significantly different (P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4% with esomeprazole 40 mg and 77.5% with lansoprazole 30 mg. Heartburn resolved at week 4 in 72% and 64% of patients who received esomeprazole and lansoprazole, respectively (P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions: With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.

AB - Background: Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim: To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods: In this multicentre, randomized, double-blind, parallel-group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg (n = 498) or lansoprazole 30 mg (n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator-assessed resolution of symptoms and safety and tolerability. Results: Time to healing was significantly different (P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4% with esomeprazole 40 mg and 77.5% with lansoprazole 30 mg. Heartburn resolved at week 4 in 72% and 64% of patients who received esomeprazole and lansoprazole, respectively (P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions: With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.

UR - http://www.scopus.com/inward/record.url?scp=14644421531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644421531&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02339.x

DO - 10.1111/j.1365-2036.2005.02339.x

M3 - Article

VL - 21

SP - 455

EP - 463

JO - Alimentary Pharmacology and Therapeutics

T2 - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -